Rxsight, Inc. Revises Revenue Guidance for the Full Year 2022
August 08, 2022 at 04:05 pm EDT
Share
RxSight, Inc. revised revenue guidance for the full year 2022. For the year, the company revised 2022 revenue guidance to a range of $44.0 million to $46.0 million, compared to prior guidance of $41.5 million to $45.5 million.
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Companyâs RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patientâs vision outcomes.
RXSIGHT, INC. 
